Table 3 Different baseline characteristics of patient responder and non-responder to vitamin D supplementation on day 3 after study drug administration. Odds ratios for 28-day mortality for vitamin D supplementation in a bivariate analysis with an interaction term for the covariates. If the interaction term was not significant, the odds ratio of treatment adjusted for covariate without interaction term was reported
|  | Vitamin D supplementation group (N = 204)* | ||
|---|---|---|---|
Responder (N = 133) | Non-responder (N = 71) | p value | |
Age, years | 64 ± 16 | 61 ± 13 | 0.19 |
Body mass index | 27.3 ± 4.7 | 27.2 ± 4.9 | 0.87 |
25-Hydroxyvitamin D, ng/ml | 13.2 ± 4.5 | 12.3 ± 4.8 | 0.19 |
1,25-Dihydroxyvitamin D, pg/ml | 48 (40–57) | 34 (24–44) | 0.05 |
Charlson Comorbidity Index | 2.8 (2.3–3.2) | 3 (2.5–3.5) | 0.59 |
SAPS 2 | 33 (30–36) | 29 (26–32) | 0.04 |
TISS | 36 (35–37) | 41 (39–42) | < 0.01 |
Male/female gender, N/N | 86/47 | 45/26 | 0.86 |
Chronic kidney disease, N (%) | 35 (26.3) | 18 (25.4) | 0.88 |
Surgical/medical and neuro admission N(%)/N(%) | 64 (48)/69 (52) | 55 (77)/16 (33) | < 0.01 |
Chronic liver disease, N (%) | 13 (9.8) | 16 (22.5) | 0.01 |
COPD, N (%) | 27 (20.3) | 10 (14) | 0.27 |
Ischemic heart disease—chronic heart failure, N (%) | 67 (50.4) | 36 (50.7) | 0.96 |
Malignant disease, N (%) | 13 (9.8) | 6 (8.5) | 0.76 |
Mechanical ventilation at enrollment, N (%) | 78 (58.6) | 55 (77.5) | 0.02 |
Use of vasopressor at enrollment, N (%) | 57 (42.9) | 47 (66.2) | < 0.01 |